Testosterone synthesis pathway

The **testosterone synthesis pathway** refers to the series of biochemical reactions that convert cholesterol into testosterone. This process primarily occurs in Leydig cells within the testes in males but also takes place at lower levels in ovaries and adrenal glands. The key steps include: 1. **Cholesterol transport** into mitochondria facilitated by proteins like STAR. 2. Conversion by **CYP11A1** enzyme into pregnenolone. 3. Sequential enzymatic reactions involving **3β-hydroxysteroid dehydrogenase**, **CYP17A1**, and **17β-hydroxysteroid dehydrogenase** ultimately produce testosterone. 4. The process is tightly regulated by luteinizing hormone from the pituitary gland via cAMP signaling pathways. 5. Disruption or pharmacological inhibition at any step can significantly alter systemic androgen levels. This is a metabolic/biochemical *pathway*, not a single molecular target like an enzyme or receptor; thus it does not fit standard definitions for therapeutic targets but rather encompasses multiple potential targets within its sequence. Drugs may target individual enzymes within this cascade for clinical purposes such as treating prostate cancer or endocrine disorders. Because "Testosterone synthesis pathway" describes a multi-step biochemical process rather than a discrete molecule/protein/receptor/enzyme/transporter/etc., it should not be considered a canonical therapeutic target on its own—rather it represents an aggregate concept encompassing several possible molecular targets.

Other names

Testosterone biosynthesis pathwayAndrogen synthesis pathwaySteroidogenesis (testosterone-specific)

Drugs targeting this pathway act by inhibiting key enzymes or regulatory steps, such as: - Inhibition of CYP17A1 to block androgen production - Inhibition of cholesterol transport into mitochondria to prevent steroidogenesis initiation - Suppression of luteinizing hormone release to reduce stimulation of Leydig cells